# Treos Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/treos-bio

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.treosbio.com
- Total disclosed funding: $8M
- Latest round: Series A (Feb 13, 2017)
- Investors on record: 1

## About

Treos Bio Limited is focused on pioneering peptide immunotherapies to improve cancer treatment, leveraging advanced peptide technology to enhance immune response against tumors.Treos Bio Limited, founded in 2013, is based in London, UK, and specializes in developing innovative immunotherapies for cancer. The company has completed 2 deals, with the most recent funding round occurring on March 31, 2021. In this round, Treos Bio raised USD 14.00 mn in Venture Debt from investors including Future Fund and Luminous Ventures. The total amount raised by the company to date is USD 8.04 mn. John Hautman is the founder of Treos Bio, who has previous entrepreneurial experience in the biotechnology sector.Treos Bio specializes in innovative off-the-shelf peptide immunotherapies, utilizing advanced peptide technology known as Promiscuous Epitope (PEPI). The flagship product, PolyPEPI1018, is a multi-peptide immunotherapy designed specifically for colorectal cancer, featuring proprietary peptides that stimulate immune responses against tumor antigens. With a focus on scalability, the peptides can be produced without the need for tumor biopsies, enhancing accessibility for varied patient demographics across global markets with a high incidence of colorectal cancer.In the most recent fiscal year of 2023, Treos Bio reported zero revenue, with an EBITDA of USD -4,447,112. The company generates revenue primarily through its PolyPEPI immunotherapy products, partnering with healthcare providers and institutions for distribution to hospitals and clinics offering cancer treatments.Following the March 31, 2021 deal, Treos Bio, Limited intends to utilize the USD 14.00 mn in funding to advance the clinical development of its novel cancer immunotherapy technology. This includes applying proprietary data science to match antigens expressed by specific cancers to individual patient genetics, which is aimed at enhancing treatment outcomes. The company is also exploring opportunities to expand into new markets with higher colorectal cancer prevalence, although specific regions and timelines for these expansions have not been disclosed.

## Funding rounds

- Series A, Feb 13, 2017, $8M — BXR Group

## Investors

- BXR Group (https://capitalatlas.ai/funds/bxr-group) — Series A